Tesamorelin vs. AOD-9604: Which peptide works better for fat reduction?

Currently, tesamorelin appears to be a more clinically studied and effective peptide for reducing visceral adipose tissue and improving metabolic health, whereas AOD-9604 remains a more experimental peptide primarily targeting fat metabolism and weight loss with less hormonal impact. In a comparison of „tesamorelin vs AOD-9604,” tesamorelin has extensive clinical trial data confirming significant reductions in visceral adipose tissue (VAT), liver fat, and metabolic risk markers, while AOD-9604 has shown more moderate fat reduction potential in animal studies and smaller human obesity trials, but without a comparable amount of long-term clinical data and regulatory approval for obesity treatment [1–8].

The two peptides work in entirely different ways in the body. Tesamorelin is a stabilized analog of growth hormone-releasing hormone (GHRH). It stimulates the pituitary gland to release endogenous growth hormone (GH), which in turn increases insulin-like growth factor-1 (IGF-1) levels and activates fat-burning pathways [1–3]. By activating the GH–IGF-1 axis, tesamorelin preferentially targets visceral adipose tissue while improving lipid metabolism, reducing liver fat, supporting mitochondrial function, and enhancing body composition.

AOD-9604 functions through a different mechanism. It is a modified fragment of human growth hormone corresponding to amino acids 176–191 and was designed to retain fat-burning properties without significantly increasing IGF-1 levels or activating the broader anabolic effects associated with GH [9–11]. Rather than strongly stimulating the entire GH hormonal system, AOD-9604 primarily enhances lipolysis and restricts lipogenesis directly in adipose tissue. Lipolysis means the breakdown of fat, whereas lipogenesis refers to the storage and creation of fat.

Tesamorelin has significantly stronger clinical evidence regarding fat reduction. In a pooled analysis of Phase III studies by Falutz et al. (2010), tesamorelin reduced visceral fat by approximately 15.4% over 26 weeks in HIV-positive individuals with abdominal fat accumulation, while simultaneously improving triglyceride levels and cholesterol ratios [3]. Long-term extension studies demonstrated sustained reduction in abdominal fat for up to 52 weeks during continued therapy [4]. Stanley et al. (2014) also demonstrated a significant reduction in both visceral adipose tissue and hepatic fat in HIV-positive individuals with excess abdominal fat [5]. In patients with HIV-associated NAFLD, Stanley et al. (2019) reported a relative reduction in hepatic fat of approximately 37% after 12 months of tesamorelin therapy [6]. These results suggest that tesamorelin primarily targets harmful visceral fat and hepatic fat, rather than solely promoting overall weight loss.

AOD-9604 also showed some fat-reducing activity, however, the available data are less consistent and less extensive. In studies on obese mice, Heffernan et al. (2001) demonstrated that AOD-9604 increased fat oxidation and reduced body weight primarily through the activation of β3-adrenergic receptors without significantly increasing IGF-1 levels or impairing glucose metabolism [12,13]. Ng et al. (2000) similarly showed that oral AOD-9604 reduced weight gain and improved fat metabolism in obese Zucker rats without inducing insulin resistance [14].

Some clinical trials on obesity have also yielded promising results. In a randomized placebo-controlled trial described by Herd et al. (2005), obese adults receiving oral AOD-9604 achieved a modest but statistically significant reduction in body weight compared to placebo over 12 weeks [15]. However, subsequent larger studies did not confirm similarly robust effects, and the development of AOD-9604 as an obesity therapy was ultimately limited [16]. In comparison to tesamorelin, evidence for long-term visceral fat reduction and improvement in metabolic health remains significantly weaker.

One of the main differences between peptides is their impact on IGF-1 and the hormonal system. Tesamorelin increases endogenous GH and IGF-1 levels, which is likely responsible for its stronger effects in reducing visceral fat, protecting lean muscle mass, liver metabolism, and mitochondrial activity [1–6]. At the same time, this means there is a possibility of side effects associated with GH, such as water retention, edema, joint pain, or minor changes in glucose levels.

AOD-9604 was specifically designed to avoid strongly increasing IGF-1 levels and broad hormonal stimulation [9–11]. Studies suggest that AOD-9604 does not significantly affect IGF-1 levels or worsen insulin sensitivity, which may be attractive to individuals seeking fat-burning support without stronger hormonal stimulation [11,17,18].

Tesamorelin also has stronger evidence regarding the improvement of overall metabolic health beyond fat loss alone. Clinical trials have shown improvements in triglycerides, cholesterol ratios, liver enzymes, inflammatory markers, mitochondrial function, and cardiovascular risk markers [3–6]. AOD-9604 appears to be more focused on fat metabolism and weight reduction without comparable evidence for broader metabolic or hepatic benefits. While preliminary studies suggest possible action in fatty liver and bone health, these data remain primarily preclinical [7–10].

Regulatory status also clearly distinguishes the two peptides. Tesamorelin has been FDA-approved under the brand name Egrifta SV for the reduction of excess abdominal adipose tissue in HIV-associated lipodystrophy [1]. In contrast, AOD-9604 has not received FDA approval for the treatment of obesity or any other medical indication and remains primarily a research compound despite its presence in some wellness circles and peptide clinics [11]. Furthermore, the World Anti-Doping Agency (WADA) classifies AOD-9604 as a prohibited substance for athletes, as it is still considered an experimental peptide [19].

In summary, tesamorelin appears to be a stronger option if the goal is clinically proven visceral fat reduction, improved fatty liver, and support for metabolic health. AOD-9604 may offer a milder and more targeted fat-burning effect with less hormonal impact and minimal IGF-1 stimulation; however, its effects in humans are less consistent and much less substantiated. The final choice depends on whether the priority is evidence-based improvement of metabolic health and visceral fat reduction, or a more experimental approach focused primarily on fat metabolism with less hormonal impact.

Disclaimer

The content is for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or therapeutic recommendation. Tesamorelin is an FDA-approved prescription medication for specific medical indications, whereas AOD-9604 remains an experimental compound and has not been approved by the FDA for the treatment of obesity. Peptides that affect fat metabolism and growth hormone pathways can carry risks and should only be used under the supervision of a qualified healthcare professional with appropriate medical evaluation and laboratory monitoring.